Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Share-based Compensation (2022 - 2025)

Axsome Therapeutics' Share-based Compensation history spans 4 years, with the latest figure at $22.7 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 3.38% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $93.8 million, up 10.01%, while the annual FY2025 figure was $93.8 million, 10.01% up from the prior year.
  • Share-based Compensation for Q4 2025 was $22.7 million at Axsome Therapeutics, down from $23.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $62.6 million in Q4 2023 and bottomed at -$12.9 million in Q2 2023.
  • The 4-year median for Share-based Compensation is $20.8 million (2024), against an average of $17.8 million.
  • The largest YoY upside for Share-based Compensation was 481.13% in 2023 against a maximum downside of 127182.61% in 2023.
  • A 4-year view of Share-based Compensation shows it stood at $10.8 million in 2022, then soared by 481.13% to $62.6 million in 2023, then tumbled by 64.87% to $22.0 million in 2024, then grew by 3.38% to $22.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Share-based Compensation are $22.7 million (Q4 2025), $23.1 million (Q3 2025), and $24.6 million (Q2 2025).